Liquidia Technologies

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapies using PRINT technology to transform patients' lives. PRINT technology is a particle engineering platform capable of precisely generating uniform drug particles, designed to enhance the safety, efficacy, and performance of various treatment methods. Currently, Liquidia is developing two product candidates: LIQ861 for the treatment of pulmonary arterial hypertension (PAH). In addition, Liquidia collaborates with leading pharmaceutical companies to apply PRINT technology across a wide range of therapeutic areas, molecular types, and routes of administration.